Articles From: ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences to Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors


ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: Live webcasts of these presentations will be accessible on the company’s website, www.acadia-pharm.com , under the investors section and an archived recording will be available on the website for two weeks following the applicable presentation.
Sign-up for ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences investment picks
Acadia Realty Trust (NYSE:AKR) today announced the core-portfolio acquisition of an 88.4% interest in 840 N Michigan Ave, an 87,000 square foot, four-story street-retail property located in Chicago, Illinois, for $144.3 million.
Sign-up for Acadia Realty Trust Acquires Street Retail Flagship on Chicago’s Magnificent Mile investment picks
Acadia Realty Trust (NYSE: AKR), today announced a 4.3% increase in the Company’s dividend for the quarter ending December 31, 2014.
Sign-up for Acadia Realty Trust Announces 4.3% Increase in Quarterly Dividend and Anticipates Special Dividend for 2014 investment picks
Acadia Realty Trust (NYSE:AKR) (the “Company”) announced today the completion of its previously announced public offering of 3,400,000 common shares of beneficial interest (“Shares”), as well as the underwriters’ full exercise of their option to purchase an additional 510,000 Shares, bringing the total issuance to 3,910,000 Shares.
Sign-up for Acadia Realty Trust Announces Closing of Common Share Offering investment picks
2014/12/12
Acadia Realty Trust (NYSE: AKR - "Acadia" or the "Company") today announced that it expects to receive approximately $108.0 million in estimated gross proceeds from its sale of 3,400,000 common shares of beneficial interest (“Shares”) to Citigroup (or approximately $124.1 million if the option to purchase additional Shares is exercised in full). Citigroup acted as the sole bookrunner for the offering.
Sign-up for Acadia Realty Trust Announces Pricing of 3.4 Million Common Share Offering investment picks
2014/10/30
Acadia Realty Trust (NYSE:AKR - "Acadia" or the "Company") today announced that it expects to receive approximately $101.2 million in estimated gross proceeds from its sale of 3,400,000 common shares of beneficial interest (“Shares”) to BofA Merrill Lynch and Barclays (or approximately $116.3 million if the option to purchase additional Shares is exercised in full). BofA Merrill Lynch and Barclays acted as joint bookrunners for the offering.
Sign-up for Acadia Realty Trust Announces Pricing of 3.4 Million Common Share Offering investment picks
Acadia Realty Trust (NYSE:AKR)("Acadia" or the "Company") today announced the sale of 3,400,000 common shares of beneficial interest of the Company (“Shares”) to BofA Merrill Lynch and Barclays, in a public offering pursuant to the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission.
Sign-up for Acadia Realty Trust Announces Sale of 3.4 Million Common Shares investment picks
2014/12/11
Acadia Realty Trust (NYSE: AKR - "Acadia" or the "Company") today announced the sale of 3,400,000 common shares of beneficial interest of the Company (“Shares”) to Citigroup, in a public offering pursuant to the Company’s effective shelf registration statement previously filed with the Securities and Exchange Commission.
Sign-up for Acadia Realty Trust Announces Sale of 3.4 Million Common Shares investment picks
Acadia Realty Trust (NYSE:AKR) today announced that its Board of Trustees has declared a special cash dividend of $0.30 per Common Share payable on January 15, 2015 to holders of record as of December 31, 2014.
Sign-up for Acadia Realty Trust Announces Special Cash Dividend of $0.30 for 2014 investment picks
Acadia Realty Trust (NYSE:AKR) today reported operating results for the quarter ended September 30, 2014.
Sign-up for Acadia Realty Trust Reports Third Quarter 2014 Operating Results investment picks
2014/10/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0974997001&sourceType=1 http://www.ccnmatthews.com/logos/20091230-Acadian200.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Acadian Timber Corp. Reports Third Quarter Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971624001&sourceType=1 http://www.ccnmatthews.com/logos/20091230-Acadian200.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Acadian Timber Corp.: Notice-2014 Third Quarter Results Conference Call and Webcast for Investors and Analysts investment picks
LAVAL, Quebec, Oct.
Sign-up for Acasti Announces Grant of Stock Options investment picks
CaPre® demonstrated a near dose proportional increase with plasma EPA and DHA levels increasing as dose increases Bioavailability of CaPre® not significantly reduced when taken with a low-fat meal versus high-fat meal; a significant advantage for the management of hypertriglyceridemic patients on low fat diets CaPre® is s afe and well tolerated, with no safety concerns LAVAL, Québec, Sept.
Sign-up for Acasti Announces Positive Top-Line Pharmacokinetic Results investment picks
LAVAL, Quebec, Oct.
Sign-up for Acasti Announces Second Quarter Results investment picks
LAVAL, Quebec, Nov.
Sign-up for Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements investment picks
Statistically significant mean placebo-adjusted reduction of triglycerides of 36.4% at 1 gram and 38.6% at 2 gram daily doses of CaPre® Statistically significant reduction of 5.3% in non-HDL-C using 2 grams of CaPre® daily (considered the most accurate risk marker for cardiovascular disease) No increases in LDL-C (bad cholesterol) and slight increases in HDL-C (good cholesterol) Clinically meaningful mean placebo-adjusted reduction in VLDL-C of 10.9% and 13.5% at 1 gram and 2 gram daily doses CaPre®, respectively (VLDL-C is considered a highly significant predictor of cardiovascular disease) Statistically significant dose dependent improvement in Omega-3 Index (a risk factor for coronary heart disease) CaPre® shown to be safe, well tolerated and effective LAVAL, Quebec, Sept.
Sign-up for Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C investment picks
Enabling system flexibility and platform scalability for industrial control applications such as digital power, renewable energy and automotive control HOUSTON , Oct.
Sign-up for Accelerate control systems and increase integration while decreasing system cost with TI's new C2000™ Piccolo™ F2807x MCUs investment picks
Brazil's C2 CPA Network selects CAKE by Accelerize as its SaaS-based performance marketing solution NEWPORT BEACH, Calif.
Sign-up for Accelerize Inc. Extends its Footprint in Latin America investment picks
Third quarter revenues increase 71.0% year over year to reach a record $4.3MM, with expected full-year revenues between $16.2MM and $16.4MM NEWPORT BEACH, Calif.
Sign-up for Accelerize Inc. Reports Third Quarter 2014 Financial Results investment picks
http://media.marketwire.com/attachments/201411/290524_ACLZ_Logo-300x120.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158597&ProfileId=051205&sourceType=1 NEWPORT BEACH, CA --
Sign-up for Accelerize Inc. Reports Third Quarter 2014 Financial Results investment picks
Technology Executive Brings Over 25 Years of Enterprise Software Operational and Marketing Experience to Help Lead Global Expansion in the Marketing Technology Industry NEWPORT BEACH, Calif.
Sign-up for Accelerize Names Santi Pierini Chief Operating Officer as Company Focuses on Strategic Growth Plan investment picks
Company intends to use increased financial flexibility to fuel strategic growth plan including expansion of its CAKE software platform into the digital advertising industry NEWPORT BEACH, Calif.
Sign-up for Accelerize's Credit Facility from Square 1 Bank Expanded to $6 Million investment picks
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will host and webcast an online educational seminar on chronic kidney disease mineral and bone disorder (CKD-MBD) with Ravi Thadhani, M.D., M.P.H. Acceleron and its collaboration partner, Celgene, are conducting phase 2 clinical trials of sotatercept in patients with end-stage renal disease with mineral and bone disorder.
Sign-up for Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder investment picks
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in four abstracts on investigational protein therapeutics sotatercept and luspatercept will be presented by Acceleron, its collaboration partner Celgene and clinical investigators at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition.
Sign-up for Acceleron Announces New Clinical Data Presentations at the 2014 American Society of Hematology Annual Meeting investment picks
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that its collaboration partner, Celgene, and investigators on the sotatercept program will present preclinical and interim clinical data at the American Society of Nephrology (ASN) Kidney Week 2014.
Sign-up for Acceleron Collaboration Partner Celgene to Present Data at the American Society of Nephrology Kidney Week 2014 investment picks
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it has initiated a phase 1 clinical trial of its novel muscle drug, ACE-083.
Sign-up for Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083 investment picks
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors.
Sign-up for Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences to Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent